CYTH: Cyclo Therapeutics, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 41.06
Enterprise Value ($M) 38.07
Book Value ($M) 0.61
Book Value / Share 0.02
Price / Book 67.32
NCAV ($M) 0.02
NCAV / Share 0.00
Price / NCAV 2,535.41

Profitability (mra)
Return on Invested Capital (ROIC) -15.21
Return on Assets (ROA) -4.73
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 0.97
Current Ratio 1.01

Balance Sheet (mrq) ($M)
Current Assets 6.57
Assets 7.16
Liabilities 6.55
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 1.08
Operating Income -20.05
Net Income -20.06
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -16.19
Cash from Investing -0.00
Cash from Financing 23.89

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
02-14 13G/A Armistice Capital, Llc 4.99 45.79
10-24 13D/A Rafael Holdings, Inc. 49.00 5.13

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-05-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: March 31, 2024 ☐Transition Report Pursuant to
2024-04-29 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark one)
2024-03-18 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one)
2023-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: September 30, 2023 ☐ Transition Report Pursua
2023-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: June 30, 2023 ☐ Transition Report Pursuant to

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-16 13,750 52,562 26.16
2024-05-15 3,010 16,466 18.28
2024-05-14 8,331 32,350 25.75
2024-05-13 192 20,592 0.93

(click for more detail)

Similar Companies
CYCC – Cyclacel Pharmaceuticals, Inc. CYCN – Cyclerion Therapeutics, Inc.
CYRX – Cryoport, Inc. DARE – Daré Bioscience, Inc.
DERM – Journey Medical Corporation


Financial data and stock pages provided by
Fintel.io




This entry was posted in . Bookmark the permalink.